<div id="readability-page-1"><div><ul> <li>Ocular Therapeutix, Inc. recently reported first-quarter 2026 results, with revenue of US$10.79 million, slightly above the prior-year period, alongside a wider net loss of US$88.61 million and basic and diluted loss per share of US$0.40.</li> <li>The combination of almost flat revenue and a meaningfully larger quarterly net loss highlights the company’s ongoing investment burden as it advances its ophthalmology pipeline.</li> <li>With first-quarter results showing a wider net loss despite stable revenue, we’ll now examine how this affects Ocular Therapeutix’s investment narrative.</li> </ul><p>Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.</p><h2>Ocular Therapeutix Investment Narrative Recap</h2><p>To own Ocular Therapeutix, you need to believe that AXPAXLI can move from promising trial data to a commercial product that eventually offsets heavy R&amp;D losses. The Q1 2026 results, with almost flat revenue but a much wider net loss, underline how dependent the short term story is on clinical and regulatory progress rather than near term earnings. For now, this loss expansion does not materially change the core near term catalyst or the key risk around AXPAXLI’s approval path.</p> <p>The most relevant recent update here is the positive Week 52 SOL‑1 data for AXPAXLI in wet AMD and management’s plan to pursue an NDA based on those results, subject to FDA discussions. This positive clinical narrative sits in clear tension with rising quarterly losses, and it puts even more weight on how regulators assess the SOL‑1 package and the ongoing SOL‑R and SOL‑X work as the company continues spending heavily ahead of any potential launch.</p> <p>But while the trial data are encouraging, investors also need to be aware that rising losses and heavy dependence on AXPAXLI could...</p> <p>Read the full narrative on Ocular Therapeutix (it's free!)</p><p>Ocular Therapeutix's narrative projects $335.8 million revenue and $68.9 million earnings by 2029.</p><p>Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 210% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cfca2898-7939-4ffe-9e6f-369980553dd9/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cfca2898-7939-4ffe-9e6f-369980553dd9/chart/quote-price"/><figcaption>OCUL 1-Year Stock Price Chart</figcaption></figure> <p>The most pessimistic analysts were already assuming strong revenue growth of about 32.6 percent a year but no profits in three years, so if you worry about heavy dependence on AXPAXLI’s trials, Q1’s deeper loss could reinforce that concern and may yet shift these expectations.</p><p>Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth just $18.00!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.</li><li>Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.</li><li>AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Find 52 companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

OCUL

<p>Ocular Therapeutix reported Q1 2026 results with revenue of $10.79 million and a net loss of $88.61 million, indicating a significant investment burden despite stable revenue. The company's future hinges on the success of its AXPAXLI trials, with a projected revenue of $335.8 million by 2029. Analysts express concerns over rising losses and dependence on AXPAXLI, with fair value estimates ranging from $18.00 to $26.00 per share.</p>

Simplywall

Ocular Therap

iShares Global Healthcare

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VG Health

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?